Skip to content

menu

Pharma in Brief logo
HomeAboutContact
Search
Close
Pharmaceuticals and life sciencesIntellectual propertyLife sciences and healthcare
View topics Archives
Subscribe

Pharma in Brief

PMPRB

Subscribe to PMPRB via RSS

Pharma in Brief’s 2024 Year in Review and Trends for 2025

Photo of Kristin WallPhoto of Christopher A. GuerreiroPhoto of Paul JorgensenPhoto of Sarah Pennington
By Kristin Wall, Christopher A. Guerreiro, Paul Jorgensen & Sarah Pennington on February 3, 2025

2024 saw no shortage of headlines in the Canadian pharma space. Here we look back on the year’s most notable legal and regulatory developments and look forward to areas to watch in 2025.

1. National pharmacare comes to Canada

In…

Drug Pricing Update: PMPRB launches consultation on Draft Guidelines for price review

Photo of Christopher A. GuerreiroPhoto of Kristin Wall
By Christopher A. Guerreiro & Kristin Wall on December 20, 2024

The Patented Medicine Prices Review Board (PMPRB or Board) has released a draft of its new price review Guidelines (the Draft Guidelines) for consultation. The Draft Guidelines outline a proposed new price-review process for Board Staff, with…

Subscribe to Pharma in Brief

Subscribe to this publication

Federal Court of Appeal confirms that the PMPRB has no jurisdiction over unpatented medicines

Photo of Christopher A. GuerreiroPhoto of Kristin Wall
By Christopher A. Guerreiro & Kristin Wall on December 4, 2024

The Federal Court of Appeal (FCA) has confirmed that the Patented Medicine Prices Review Board (PMPRB or Board) does not have jurisdiction over the prices of unpatented medicines. In doing so, the FCA overturned decisions of…

Drug pricing: PMPRB launches next phase of the Guidelines consultation

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on June 28, 2024

The Patented Medicine Prices Review Board (PMPRB) has released a new Discussion Guide for consultation on new price review Guidelines. The Discussion Guide outlines a proposed new price review process and requests stakeholder feedback on several specific topics…

Drug pricing: PMPRB announces next steps in Guidelines consultation

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on April 14, 2024

The Patented Medicine Prices Review Board (PMPRB) has announced new details regarding the progress of its consultation on new price review Guidelines.

Phase 2: Discussion Guide

The next phase of the PMPRB’s consultation will begin in summer 2024…

Drug pricing: PMPRB releases “What We Learned” Report on guidelines consultation

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on February 16, 2024

The Patented Medicine Prices Review Board (PMPRB or Board) has released a “What We Learned” Report (the Report), marking the next step along the path to new Guidelines. The Report was prepared by Phoenix Strategic Perspectives Inc.…

Federal Court upholds PMPRB jurisdiction based on “clinical similarities”

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on January 15, 2024

The Federal Court (FC) has refused to overturn a decision of the Patented Medicine Prices Review Board (PMPRB or Board) that found that a patent can pertain to a medicine based on “clinical similarities” to the…

Pharma in Brief’s 2023 Year in Review and Trends for 2024

Photo of Kristin WallPhoto of Christopher A. GuerreiroPhoto of Paul JorgensenPhoto of Pardeep Heir
By Kristin Wall, Christopher A. Guerreiro, Paul Jorgensen & Pardeep Heir on January 10, 2024

As you start the new year, allow us to recap 2023’s important legal and regulatory developments for Canadian pharma. We also flag what to watch out for in 2024. 

The most significant legal development in 2023 was the introduction of…

Drug pricing: PMPRB releases scoping paper to consult on new Guidelines

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on November 12, 2023

The Patented Medicine Prices Review Board (PMPRB) has released a scoping paper on themes and questions to develop new price review Guidelines. The scoping paper also includes information on how stakeholders can participate in the consultation.

The deadline…

Drug pricing: PMPRB announces framework for new guidelines consultation

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on October 26, 2023

The Patented Medicine Prices Review Board (PMPRB) has announced a framework for the launch of its consultation on new guidelines, beginning with a scoping paper to be published in advance of Policy Roundtable sessions to be held December…

Post navigation

Older Posts 

Pharma in Brief

LinkedIn Twitter Facebook RSS YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

Stay up-to-date with legal and regulatory developments affecting the pharmaceutical industry. Pharma in Brief provides timely updates with a focus on the key take-away you need to know.

Read more

Topics

Archives

Copyright © 2025, Norton Rose Fulbright LLP. All rights reserved.